Chlamydia Pneumoniae Infection
The intersection of oncology and pharmacology continually unveils groundbreaking insights. Among the frontrunners in cancer therapeutics is doxorubicin hydrochloride. This potent chemotherapeutic agent has reshaped cancer treatment paradigms. However, its association with DEA No. 9648 positions it uniquely in both regulatory and therapeutic contexts. The exploration of this agent in tandem with physical medicine and …